Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 9;22(22):12123.
doi: 10.3390/ijms222212123.

Urinary Protein and Peptide Markers in Chronic Kidney Disease

Affiliations
Review

Urinary Protein and Peptide Markers in Chronic Kidney Disease

Natalia Chebotareva et al. Int J Mol Sci. .

Abstract

Chronic kidney disease (CKD) is a non-specific type of kidney disease that causes a gradual decline in kidney function (from months to years). CKD is a significant risk factor for death, cardiovascular disease, and end-stage renal disease. CKDs of different origins may have the same clinical and laboratory manifestations but different progression rates, which requires early diagnosis to determine. This review focuses on protein/peptide biomarkers of the leading causes of CKD: diabetic nephropathy, IgA nephropathy, lupus nephritis, focal segmental glomerulosclerosis, and membranous nephropathy. Mass spectrometry (MS) approaches provided the most information about urinary peptide and protein contents in different nephropathies. New analytical approaches allow urinary proteomic-peptide profiles to be used as early non-invasive diagnostic tools for specific morphological forms of kidney disease and may become a safe alternative to renal biopsy. MS studies of the key pathogenetic mechanisms of renal disease progression may also contribute to developing new approaches for targeted therapy.

Keywords: biomarkers; chronic kidney disease; proteomics; urine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Kidney Disease Improving Global Outcomes (KDIGO) KDIGO Clinical Practice Guideline for Glomerulonephritis. Nature Publishing Group; New York, NY, USA: 2012. Kidney International Supplements.
    1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002;39:1–266. - PubMed
    1. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L., Kelepouris E., Klag M.J., et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Circulation. 2003;108:2154–2169. doi: 10.1161/01.CIR.0000095676.90936.80. - DOI - PubMed
    1. Alani H., Tamimi A., Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J. Nephrol. 2014;3:156–168. doi: 10.5527/wjn.v3.i4.156. - DOI - PMC - PubMed
    1. Hsu C., Ordoñez J., Chertow G., Fan D., McCulloch C., Go A. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74:101–107. doi: 10.1038/ki.2008.107. - DOI - PMC - PubMed